Question 1

What is Lanadelumab?

Accepted Answer

Lanadelumab is a laboratory-made protein known as a monoclonal antibody. It works by targeting and blocking the activity of an enzyme in the blood called plasma kallikrein.

By inhibiting this enzyme, the medication helps control the production of bradykinin, a substance that causes blood vessels to leak fluid into surrounding tissues. This process helps manage the underlying biological triggers that lead to sudden and severe swelling episodes.

Question 2

What is Lanadelumab used for?

Accepted Answer

Lanadelumab is used to treat routine prevention of hereditary angioedema attacks.

Question 3

How does Lanadelumab work?

Accepted Answer

Mechanism of Action

Lanadelumab is a type of protein called a monoclonal antibody. It is designed to target and block the activity of an enzyme in the blood known as plasma kallikrein.

In individuals with hereditary angioedema (HAE), plasma kallikrein becomes overactive. This overactivity leads to the excessive release of a peptide called bradykinin. Bradykinin is responsible for making blood vessels leak fluid into nearby tissues, which results in the sudden and severe swelling attacks associated with the condition.

By inhibiting plasma kallikrein, lanadelumab helps to:

Limit the production of bradykinin.

Prevent the fluid leakage that causes swelling.

Reduce the overall number of HAE attacks.

This medication is intended for long-term prevention. It works continuously in the system to keep protein levels regulated, rather than treating the symptoms of an active attack once it has begun.

Question 4

What are the brand names for Lanadelumab?

Accepted Answer

Lanadelumab is sold under the brand name Takhzyro .

Question 5

What are the active ingredients in Lanadelumab?

Accepted Answer

The active ingredient in Lanadelumab is lanadelumab .

Question 6

What are the side effects of Lanadelumab?

Accepted Answer

Common side effects of Lanadelumab may include:

injection site reactions

headache

upper respiratory tract infection

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Lanadelumab?

Accepted Answer

Lanadelumab belongs to the monoclonal antibody drug class.

Question 8

What is the dosage of Lanadelumab and how do I take it?

Accepted Answer

Administration

Lanadelumab is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. Common injection sites include the stomach area, the front of the thighs, or the back of the upper arms. It is important to rotate the injection site each time a dose is given. This medication can be self-administered or given by a caregiver after receiving proper training from a healthcare provider.

Preparation

Before using the medication, it should be removed from the refrigerator and allowed to reach room temperature for approximately 15 to 30 minutes. Do not shake the vial or syringe. The liquid should be clear to slightly yellow; do not use it if it is cloudy, discolored, or contains large particles. Once the medication is drawn into a syringe, it must be used immediately.

Frequency and Schedule

This medication is typically administered every two weeks or every four weeks. A healthcare provider will determine the appropriate schedule based on the patient's age and how well the condition is controlled. It is intended for long-term prevention and should be used regularly even if no symptoms are present. It is not used to treat an acute attack of hereditary angioedema once it has started.

Missed Dose

If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular schedule resumed. Do not administer two doses at the same time to make up for a missed one.

Question 9

Is Lanadelumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is currently unknown whether lanadelumab can cause harm to an unborn baby or increase the risk of miscarriage. Research in humans is insufficient to determine if there is a drug-associated risk of major birth defects.

Because lanadelumab is a monoclonal antibody, it is expected to cross the placenta as pregnancy progresses. The potential for effects on the fetus is likely to be greater during the second and third trimesters. If you are pregnant or planning to become pregnant, discuss the potential risks and benefits of this treatment with your healthcare provider.

Breastfeeding

It is not known if lanadelumab passes into human breast milk, how it affects milk production, or if it has any effect on a nursing infant. If you are breastfeeding or planning to breastfeed, consult your doctor to weigh the benefits of breastfeeding against the potential risks to the infant.

Question 10

What forms and strengths does Lanadelumab come in?

Accepted Answer

Lanadelumab is supplied as a sterile, preservative-free solution for injection under the skin (subcutaneous use). It is available in two primary delivery formats:

Single-dose vials: Glass vials containing the liquid medication.

Single-dose prefilled syringes: Ready-to-use syringes containing a fixed dose of the medication.

The solution is typically clear to slightly opalescent and colorless to slightly yellow. It is available in different strengths to accommodate different age groups, including adults, adolescents, and pediatric patients. Each vial or syringe is intended for a single use only and should be discarded after the dose is administered.

Question 11

What is the FDA approval status of Lanadelumab?

Accepted Answer

FDA Approval History

Lanadelumab was first approved by the U.S. Food and Drug Administration (FDA) in August 2018. It was initially indicated for the prevention of hereditary angioedema (HAE) attacks in patients 12 years of age and older. In February 2023, the FDA expanded the approved use to include pediatric patients aged 2 to less than 12 years.

Regulatory Designations

During its development and review, the FDA granted lanadelumab several special designations to facilitate its availability for a rare condition:

Orphan Drug: This status is given to medications intended for the treatment of rare diseases affecting fewer than 200,000 people in the United States.

Breakthrough Therapy: This designation is intended to expedite the development and review of drugs for serious conditions where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies.

Priority Review: This designation directs the FDA's attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.

Safety and Monitoring

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) programs required by the FDA for lanadelumab. It is approved specifically for the prevention of HAE attacks and is not indicated for the treatment of acute attacks. The medication is administered via subcutaneous injection by a healthcare professional or through self-administration after proper training.

Question 12

What should I know about Lanadelumab and cost?

Accepted Answer

Insurance and Prior Authorization

Lanadelumab is classified as a specialty biologic medication. Most insurance providers require prior authorization, a process where your healthcare provider must submit documentation to justify the medical necessity of the drug before coverage is approved.

Specialty Pharmacy Services

Because it is a high-cost medication requiring specific handling, lanadelumab is usually dispensed through specialty pharmacies. These pharmacies coordinate with insurance companies to determine your specific co-pay or coinsurance amounts and arrange for the delivery of the medication.

Financial Assistance Programs

Several options may be available to help reduce the cost of treatment:

Co-pay Assistance: Eligible patients with commercial insurance may qualify for co-pay cards that can significantly reduce out-of-pocket costs.

Patient Assistance Programs: These programs may provide the medication at no cost to individuals who are uninsured or meet certain income requirements.

Support Programs: Manufacturer-sponsored programs often provide dedicated case managers to help patients navigate insurance claims and identify financial resources.

Patients are encouraged to contact their insurance provider and the medication's manufacturer to understand the specific costs and support options available to them.

Lanadelumab

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?